LIVIVO - Search results -

Search results

Result 1 - 10 of total 249

Search options

Book: Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019

Kiltz, Uta

Langfassung zur S3-Leitlinie : AWMF-Leitlinien Register Nummer: 060/003, Entwicklungsstufe: S3, Version: 2018 : evidenzbasierte leitlinie

(Zeitschrift für Rheumatologie ; Band 78, Supplement 1 (Dezember 2019))

2019

Title variant	Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019
Institution	Deutsche Gesellschaft für Rheumatologie
Author's details	Deutsche Gesellschaft für Rheumatologie e.V. ; U.Kiltz, J. Braun, A. Becker [und 22 weitere]
Series title	Zeitschrift für Rheumatologie ; Band 78, Supplement 1 (Dezember 2019)
Collection
Language	German
Size	S64 Seiten
Publisher	Springer Medizin
Publishing place	Heidelberg
Publishing country	Germany
Document type	Book
HBZ-ID	HT020327484
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Uh III Zs 128 -78,Suppl.1-	verfügbar in Königswinter	Königswinter

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Book: Langfassung zur S2e-Leitlinie Gichtarthritis (fachärztlich)

Kiltz, Uta

evidenzbasierte Leitlinie der Deutschen Gesellschaft für Rheumatologie (DGRh) = Full version of the S2e guidelines on gouty arthritis : evidence-based guidelines of the German society of Rheumatology (DGRh)

(Zeitschrift für Rheumatologie ; Band 75, Supplement 2 (August 2016))

2016

Title variant	Full version of the S2e guidelines on gouty arthritis
Institution	Deutsche Gesellschaft für Rheumatologie
Author's details	U. Kiltz, R. Alten, M. Fleck, K. Krüger, B. Manger, U. Müller-Ladner, H. Nüßlein, M. Reuss-Borst, A. Schwarting, H. Schulze-Koops, A. Tausche, J. Braun
Series title	Zeitschrift für Rheumatologie ; Band 75, Supplement 2 (August 2016)
Collection
Language	German
Size	Seite S9-S60
Publisher	Springer Medizin
Publishing place	Heidelberg
Publishing country	Germany
Document type	Book
HBZ-ID	HT019068462
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Uh III Zs 128 -75,Suppl.2-	verfügbar in Königswinter	Königswinter

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book: Ixekizumab

Kiltz, Uta

Interleukin-17A-Inhibitor zur zielgerichteten Therapie der Psoriasis-Arthritis nach DMARD

(Drug report ; 12. Jahrgang, Heft 10 (August 2018))

2018

Author's details	Herausgeber PD Dr. Uta Kiltz
Series title	Drug report ; 12. Jahrgang, Heft 10 (August 2018)
Collection
Language	German
Size	19 Seiten, Illustrationen, Diagramme
Publisher	Thieme
Publishing place	Stuttgart
Publishing country	Germany
Document type	Book
HBZ-ID	HT019809504
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
Zs A 6601 -12,10-	verfügbar in Königswinter	Königswinter

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Thesis: Erfassung der Funktionsfähigkeit und Erhalt der gesundheitsbezogenen Lebensqualität bei Patienten mit axialer Spondyloarthritis

Kiltz, Uta

2017

Institution	Ruhr-Universität Bochum
Author's details	von Dr. med. Uta Kiltz
Language	German
Size	64 Blätter, Illustrationen
Publishing place	Bochum
Publishing country	Germany
Document type	Book ; Thesis
Thesis / German Habilitation thesis	Habilitationsschrift, Ruhr-Universität Bochum, 2017
Note	Enthält 8 Aufsätze
HBZ-ID	HT019761748
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2019 E 149	order for loan	Magazin

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Erste Klassifikationskriterien für durch Kalziumpyrophosphatablagerungen verursachte Erkrankungen – Übersetzung, Erläuterung und Bewertung.

Braun, Jürgen / Krekeler, Martin / Kiltz, Uta

Zeitschrift fur Rheumatologie

2024 Volume 83, Issue 4, Page(s) 306–315

Abstract: Aim: For diseases caused by calcium pyrophosphate deposition (CPPD), validated classification criteria were previously lacking. In this article the recently developed and validated classification criteria are translated, explained, and assessed.: ... ...

Title translation	First classification criteria for diseases caused by calcium pyrophosphate deposition (CPPD)-Translation, explanation and assessment.
Abstract	Aim: For diseases caused by calcium pyrophosphate deposition (CPPD), validated classification criteria were previously lacking. In this article the recently developed and validated classification criteria are translated, explained, and assessed. Methods: In recent years a multinational research group developed classification criteria for CPPD disease with the support by the European Alliance of Associations for Rheumatology (EULAR) and the American College of Rheumatology (ACR), following an established method. The developed criteria were finally validated in an independent cohort. The translation and annotation of the new first classification criteria were carried out in an iterative procedure in consensus with the authors. Results: The presence of a crowned dens syndrome or calcium pyrophosphate crystals in the synovial fluid in patients with pain, swelling or sensitivity of the joints (entry criterion) is sufficient for the classification as CPPD disease, where the symptoms cannot be completely explained by another rheumatic disease (exclusion criterion). If these symptoms are not present, a count of more than 56 points based on weighted criteria comprised of clinical features and the results of laboratory and imaging investigations can be included for classification as a CPPD disease. These criteria had a sensitivity of 92.2% and a specificity of 87.9% in the derivation cohorts (190 CPPD cases and 148 mimics), whereas the sensitivity was 99.2% and the specificity 92.5% in the validation cohorts (251 CPPD cases and 162 mimics). Conclusion: The ACR/EULAR classification criteria 2023 of a CPPD disease will facilitate clinical research in this field. The use in the clinical routine will show how practical the criteria are.
MeSH term(s)	Chondrocalcinosis/classification ; Chondrocalcinosis/diagnosis ; Humans ; Sensitivity and Specificity ; Germany ; Reproducibility of Results ; Translating ; Rheumatology/standards ; Calcium Pyrophosphate/metabolism ; Terminology as Topic ; Diagnosis, Differential
Chemical Substances	Calcium Pyrophosphate (X69NU20D19)
Language	German
Publishing date	2024-02-21
Publishing country	Germany
Document type	English Abstract ; Journal Article
ZDB-ID	124985-x
ISSN	1435-1250 ; 0340-1855 ; 0301-6382
ISSN (online)	1435-1250
ISSN	0340-1855 ; 0301-6382
DOI	10.1007/s00393-024-01482-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.128: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis.

Braun, Juergen / Kiltz, Uta / Baraliakos, Xenofon

Expert opinion on biological therapy

2023 Volume 23, Issue 2, Page(s) 195–206

Abstract: Introduction: Spondyloarthritides (SpA) such as axial spondyloarthritis (axSpA) including ankylosing spondylitis (AS) and psoriatic arthritis (PsA) including psoriasis are chronic immune-mediated disorders with involvement of tumor necrosis factor (TNF), ...

Abstract	Introduction: Spondyloarthritides (SpA) such as axial spondyloarthritis (axSpA) including ankylosing spondylitis (AS) and psoriatic arthritis (PsA) including psoriasis are chronic immune-mediated disorders with involvement of tumor necrosis factor (TNF), interleukin (IL)-17 cytokines, and janus kinases (JAK) in their pathogenesis, with IL-23 clearly also playing a role in psoriasis, PsA, and chronic inflammatory bowel diseases. Areas covered: In this narrative review, we focus on a biologic disease modifying anti-rheumatic drug (bDMARD), the bispecific IL-17A and IL-17 F inhibitor bimekizumab, and a targeted synthetic (ts) DMARD, the JAK inhibitor (i) filgotinib - emerging agents for the treatment of axSpA. Upadacitinib, another JAKi that has recently been reviewed intensively by us is already approved for axSpA and PsA in Europe. Expert opinion: In contrast to inhibition of IL-17, JAKi also work in rheumatoid arthritis (RA), while agents inhibiting IL-17 are not, even though some effect may be there. Indeed, 4 JAKi including filgotinib are approved for RA. There are several head-to-head trials with bimekizumab in plaque psoriasis. The last one showed that the bispecific inhibition of IL-17A and IL-17 F with bimekizumab may indeed be superior to inhibition of IL-17A alone with 300 mg secukinumab (usual dosage). Whether this is also the case for treatment of axSpA and PsA remains to be shown.
MeSH term(s)	Humans ; Interleukin-17 ; Arthritis, Psoriatic/drug therapy ; Spondylarthritis/drug therapy ; Spondylitis, Ankylosing/drug therapy ; Psoriasis/drug therapy ; Arthritis, Rheumatoid/drug therapy ; Antirheumatic Agents/therapeutic use ; Antirheumatic Agents/pharmacology
Chemical Substances	Interleukin-17 ; Antirheumatic Agents
Language	English
Publishing date	2023-01-03
Publishing country	England
Document type	Review ; Journal Article
ZDB-ID	2052501-1
ISSN	1744-7682 ; 1471-2598
ISSN (online)	1744-7682
ISSN	1471-2598
DOI	10.1080/14712598.2022.2156283
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6094: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Assessments und Outcome-Parameter bei axialer Spondyloarthritis in klinischen Studien und in der täglichen Praxis.

Kiltz, Uta / Lalazi, Brikena / Baraliakos, Xenofon

Zeitschrift fur Rheumatologie

2023 Volume 82, Issue 5, Page(s) 380–388

Abstract: A standardized documentation of the clinical manifestation and patient-reported outcome (PRO) of patients with axial spondylarthritis (axSpA) is necessary in order to assess the disease with respect to disease activity and severity and to achieve the ... ...

Title translation	Assessments and outcome parameters for axial spondylarthritis in clinical studies and routine practice.
Abstract	A standardized documentation of the clinical manifestation and patient-reported outcome (PRO) of patients with axial spondylarthritis (axSpA) is necessary in order to assess the disease with respect to disease activity and severity and to achieve the foundations for clinical decisions. The standardized documentation refers to domains such as disease activity, quality of life, functional capacity and ability to work but also to individual aspects, such as pain, arthritis and enthesitis. The domains as well as the individual aspects are mainly collected directly from PROs using a self-report questionnaire. An exception is the clinical examination of the inflammatory involvement of joints, entheses and the physical examination of spinal mobility. In interventional studies, status or response criteria are used to quantify changes. The lack of objective clinical criteria for documentation of inflammatory activity poses a particular challenge in axSpA, therefore, the PROs need to be interpreted critically taking objective disease parameters into consideration. Most instruments were developed in the 1990s in Bath, UK and in the last 15 years by the Assessments in Axial Spondylarthritis International Society (ASAS) for use in studies.
MeSH term(s)	Humans ; Spondylarthritis/diagnosis ; Quality of Life ; Spondylitis, Ankylosing/diagnosis ; Spine ; Axial Spondyloarthritis
Language	German
Publishing date	2023-05-30
Publishing country	Germany
Document type	English Abstract ; Journal Article ; Review
ZDB-ID	124985-x
ISSN	1435-1250 ; 0340-1855 ; 0301-6382
ISSN (online)	1435-1250
ISSN	0340-1855 ; 0301-6382
DOI	10.1007/s00393-023-01357-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.128: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Correspondence on "Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial" by Molto

Kiltz, Uta / Braun, Juergen

Annals of the rheumatic diseases

2021 Volume 82, Issue 12, Page(s) e229

MeSH term(s)	Humans ; Spondylitis, Ankylosing ; Spondylarthritis/drug therapy ; Axial Spondyloarthritis
Language	English
Publishing date	2021-11-01
Publishing country	England
Document type	Randomized Controlled Trial ; Letter ; Comment
ZDB-ID	7090-7
ISSN	1468-2060 ; 0003-4967
ISSN (online)	1468-2060
ISSN	0003-4967
DOI	10.1136/annrheumdis-2021-221423
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.114: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 167: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Trends in health care of patients with vasculitides, including giant cell arteritis, Takayasu arteritis, ANCA-associated vasculitis and Behçet's disease: cross-sectional data of the German National Database 2007-2021.

Henes, Jörg / Richter, Jutta G / Thiele, Katja / Kiltz, Uta / Callhoff, Johanna / Albrecht, Katinka

Rheumatology international

2024 Volume 44, Issue 3, Page(s) 497–507

Abstract: The aim of this study is to present the current care situation of patients with giant cell arteritis (GCA), Takayasu arteritis (TAK), ANCA-associated vasculitis (AAV) and Behçet's disease (BD). Trends over the last 15 years will reflect improvements and ... ...

Abstract	The aim of this study is to present the current care situation of patients with giant cell arteritis (GCA), Takayasu arteritis (TAK), ANCA-associated vasculitis (AAV) and Behçet's disease (BD). Trends over the last 15 years will reflect improvements and remaining deficits in the management of vasculitides. Consecutive cross-sectional data from patients with vasculitides from the German National Database (NDB) of the Collaborative Arthritis Centres between 2007 and 2021 were included. Medication, physician- and patient-reported outcomes on disease activity and disease burden, inpatient stays and occupational participation are compared for different vasculitis entities and over time. Employment rates were compared to German population rates. Between 502 and 854 vasculitis patients were annually documented. GCA and AAV were the most common vasculitides. Median disease duration ranged from 2 to 16 years. Over the years, glucocorticoids decreased in proportion and dose, most markedly in GCA and TAK, while biologic therapies increased up to 27%. Physicians rated disease activity as low for the vast majority of patients, while patients-reported moderate outcomes in many dimensions. PROs remained largely unchanged. The proportion of employed patients (< 65 years) increased from 47 to 57%. In recent years, biologics are increasingly used in patients with vasculitides, while glucocorticoids decreased significantly. PRO's have not improved. Work participation increased but remains lower than that in the German population.
MeSH term(s)	Humans ; Giant Cell Arteritis/drug therapy ; Giant Cell Arteritis/epidemiology ; Behcet Syndrome/diagnosis ; Behcet Syndrome/drug therapy ; Behcet Syndrome/epidemiology ; Takayasu Arteritis/drug therapy ; Takayasu Arteritis/epidemiology ; Cross-Sectional Studies ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/epidemiology ; Glucocorticoids/therapeutic use ; Delivery of Health Care ; Giant Cells
Chemical Substances	Glucocorticoids
Language	English
Publishing date	2024-01-05
Publishing country	Germany
Document type	Journal Article
ZDB-ID	8286-7
ISSN	1437-160X ; 0172-8172
ISSN (online)	1437-160X
ISSN	0172-8172
DOI	10.1007/s00296-023-05508-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1639: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Management of Axial Spondyloarthritis - Insights into Upadacitinib.

Braun, Jürgen / Kiltz, Uta / Baraliakos, Xenofon

Drug design, development and therapy

2022 Volume 16, Page(s) 3609–3620

Abstract: Although the pathogenesis of spondyloarthritis (SpA) has still not been elucidated our options to treat SpA have definitely improved in the last decades. There are two main types of SpA: (i) axial spondyloarthritis (axSpA), also covering the classical ... ...

Abstract	Although the pathogenesis of spondyloarthritis (SpA) has still not been elucidated our options to treat SpA have definitely improved in the last decades. There are two main types of SpA: (i) axial spondyloarthritis (axSpA), also covering the classical ankylosing spondylitis (AS) which is largely equivalent to radiographic (r)-axSpA but different from non-radiographic (nr)-axSpA, and (ii) peripheral SpA (pSpA) also covering psoriatic arthritis (PsA) as the main subtype. The subtype nr-axSpA has historically developed because the approval of drugs for AS did not cover forms without structural changes in the sacroiliac joints which is mandatory in the 1984 New York criteria. The definitions for axSpA are based on the 2009 Assessments in AxSpA International Society (ASAS) classification criteria. Several biologic disease modifying anti-rheumatic drugs (bDMARDs) such as the tumor necrosis factor alpha inhibitors (TNFi) and the interleukin-17-inhibitors (IL-17i) are approved mostly for the whole spectrum of SpA including axSpA and PsA but L-17i does not work in inflammatory bowel disease (IBD). Targeted synthetic (ts) DMARDs cover mainly the janus kinase (JAK)-inhibitors which have recently been developed to inhibit inflammation in several rheumatic and other immune mediated diseases such as IBD. Indeed, the physiologic mechanism of JAK-mediated signal transduction has been recognized as an important target because the inhibition of its actions was shown to successfully work as a therapeutic mechanism. There are now 4 small molecule JAK inhibitors (JAKi) that currently play a role in rheumatology with variable selectivity for the four different JAK isoforms: tofacitinib, baricitinib, upadacitinib and filgotinib. In this review, we summarize current clinical trial data and evaluate the use of the JAK1 selective inhibitor upadacitinib in the treatment of axSpA, including nr-axSpA and r-axSpA. Even though the efficacy and safety of upadacitinib over shorter periods of time has been convincing to date, long-term trials are needed to fully establish its performance and also evaluate the safety at higher doses, and its use in PsA.
MeSH term(s)	Humans ; Tumor Necrosis Factor-alpha ; Axial Spondyloarthritis ; Interleukin-17 ; Janus Kinase Inhibitors/therapeutic use ; Arthritis, Psoriatic/drug therapy ; Spondylarthritis/drug therapy ; Spondylitis, Ankylosing/drug therapy ; Antirheumatic Agents/therapeutic use ; Biological Products/therapeutic use ; Inflammatory Bowel Diseases/drug therapy ; Janus Kinases
Chemical Substances	upadacitinib (4RA0KN46E0) ; Tumor Necrosis Factor-alpha ; Interleukin-17 ; Janus Kinase Inhibitors ; Antirheumatic Agents ; Biological Products ; Janus Kinases (EC 2.7.10.2)
Language	English
Publishing date	2022-10-19
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	2451346-5
ISSN	1177-8881 ; 1177-8881
ISSN (online)	1177-8881
ISSN	1177-8881
DOI	10.2147/DDDT.S330413
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito